Alfuzosin HCl(SL 77499-10 HCl)

Molecular Weight (MW)	425.91
Formula	C19H27N5O4.HCl
CAS No.	81403-68-1
Storage	-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)	DMSO: 85 mg/mL (199.6 mM)
Water: 85 mg/mL (199.6 mM)
Ethanol: 85 mg/mL (199.6 mM)
Other info	Chemical Name: N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furancarboxamide, monohydrochloride InChi Key: YTNKWDJILNVLGX-UHFFFAOYSA-N InChi Code: InChI=1S/C19H27N5O4.ClH/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19;/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23);1H SMILES Code: O=C(C1OCCC1)NCCCN(C2=NC(N)=C3C=C(OC)C(OC)=CC3=N2)C.[H]Cl
Synonyms	SL-77499; Alfetim; alfusozine; alfuzosin; SL 77499; SL77499; alfuzosin hydrochloride; alphuzosine; Benestan; Urion; UroXatral; Xatral

Molecular Weight (MW)

425.91

Formula

C19H27N5O4.HCl

CAS No.

81403-68-1

Storage

-20℃ for 3 years in powder form

-80℃ for 2 years in solvent

Solubility (In vitro)

DMSO: 85 mg/mL (199.6 mM)

Water: 85 mg/mL (199.6 mM)

Ethanol: 85 mg/mL (199.6 mM)

Other info

Chemical Name: N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furancarboxamide, monohydrochloride

InChi Key: YTNKWDJILNVLGX-UHFFFAOYSA-N

InChi Code: InChI=1S/C19H27N5O4.ClH/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19;/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23);1H

SMILES Code: O=C(C1OCCC1)NCCCN(C2=NC(N)=C3C=C(OC)C(OC)=CC3=N2)C.[H]Cl

Synonyms

SL-77499; Alfetim; alfusozine; alfuzosin; SL 77499; SL77499; alfuzosin hydrochloride; alphuzosine; Benestan; Urion; UroXatral; Xatral

In Vitro	In vitro activity: Alfuzosin significantly increases whole-cell peak sodium (hNa(v)1.5) current, increases the probability of late hNa(v)1.5 single-channel openings, and significantly shortens the slow time constant for recovery from inactivation. Alfuzosin also increases hNa(v)1.5 burst duration and number of openings per burst between 2- and 3-fold. Alfuzosin shows a concentration-dependent relaxing effect on rabbit corpus cavernosum (CC) pre-contracted by 10 mM phenylephrine.
In Vivo	Alfuzosin (300 nM) significantly prolongs action potential duration (APD)(60) in rabbit Purkinje fibers and QT in isolated rabbit hearts. Alfuzosin enhances the number and amplitude of erections induced by apomorphine in spontaneous hypertensive rats (SHR). Alfuzosin behaves as an alpha-adrenergic antagonist blocking the contractions induced by exogenous noradrenaline without altering spikes in both portions of the vas deferens. Alfuzosin (0.03-0.3 mg kg-1, i.v.) markedly inhibits pressor responses produced by the alpha 1-selective agonist, Cirazoline but inhibits only slightly responses to the alpha 2-selective agonist, UK 14,304, in the pithed rat. Alfuzosin (1 mg kg-1, i.v.) has minimal effects against responses mediated by stimulation of prejunctional alpha 2-receptors (UK 14,304-induced inhibition of sympathetic tachycardia). Alfuzosin (0.001-1 mg kg-1, i.v.) and Prazosin (0.001-0.3 mg kg-1, i.v.) produces dose-related inhibition of the increases in urethral pressure caused by stimulation of sympathetic hypogastric nerves in the anaesthetized cat.
Animal model	Rats amd cats
Formulation & Dosage	0.001-1 mg kg-1, i.v.
References	J Pharmacol Exp Ther. 2008 Feb;324(2):427-33; Eur Urol. 2004 Jan;45(1):110-6

In Vitro

In vitro activity: Alfuzosin significantly increases whole-cell peak sodium (hNa(v)1.5) current, increases the probability of late hNa(v)1.5 single-channel openings, and significantly shortens the slow time constant for recovery from inactivation. Alfuzosin also increases hNa(v)1.5 burst duration and number of openings per burst between 2- and 3-fold. Alfuzosin shows a concentration-dependent relaxing effect on rabbit corpus cavernosum (CC) pre-contracted by 10 mM phenylephrine.

In Vivo

Alfuzosin (300 nM) significantly prolongs action potential duration (APD)(60) in rabbit Purkinje fibers and QT in isolated rabbit hearts. Alfuzosin enhances the number and amplitude of erections induced by apomorphine in spontaneous hypertensive rats (SHR). Alfuzosin behaves as an alpha-adrenergic antagonist blocking the contractions induced by exogenous noradrenaline without altering spikes in both portions of the vas deferens. Alfuzosin (0.03-0.3 mg kg-1, i.v.) markedly inhibits pressor responses produced by the alpha 1-selective agonist, Cirazoline but inhibits only slightly responses to the alpha 2-selective agonist, UK 14,304, in the pithed rat. Alfuzosin (1 mg kg-1, i.v.) has minimal effects against responses mediated by stimulation of prejunctional alpha 2-receptors (UK 14,304-induced inhibition of sympathetic tachycardia). Alfuzosin (0.001-1 mg kg-1, i.v.) and Prazosin (0.001-0.3 mg kg-1, i.v.) produces dose-related inhibition of the increases in urethral pressure caused by stimulation of sympathetic hypogastric nerves in the anaesthetized cat.

Animal model

Rats amd cats

Formulation & Dosage

0.001-1 mg kg-1, i.v.

References

J Pharmacol Exp Ther. 2008 Feb;324(2):427-33; Eur Urol. 2004 Jan;45(1):110-6

CAS NO:	81403-68-1
规格:	≥98%

包装	价格(元)
10mg	询价
25mg	询价
50mg	询价
100mg	询价
250mg	询价
500mg	询价
1g	询价